| colestipol vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death and non fatal MI | no data | | Coronary death | 0.64 [0.37 1.10] | p=1.00 | 0 | 2528 | 5 | UCS (Dorr),Gross,Ryan,Gundersen,Ruoff, | | cardiac death | 0.59 [0.33 1.04] | p=1.00 | 0 | 2318 | 2 | UCS (Dorr),Ruoff, | | MACE | no data | | Non fatal MI | no data | | All cause death | 0.74 [0.48 1.12] | p=1.00 | 0 | 2528 | 5 | UCS (Dorr),Gross,Ryan,Gundersen,Ruoff, | | non cardiovascular death | 1.04 [0.53 2.04] | p=1.00 | 0 | 2476 | 4 | UCS (Dorr),Ryan,Gundersen,Ruoff, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | 0.98 [0.14 6.99] | p=1.00 | 0 | 2278 | 1 | UCS (Dorr), | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
